Skip to main content
SpringerLink
Log in

Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

The immunotherapy combined chemotherapy has been the standard treatment strategy for extensive-stage small lung cancer (ES-SCLC). The CREST trial reported consolidative thoracic radiotherapy (cTRT) improved overall survival (OS) for ES-SCLC with intrathoracic residual after chemotherapy. In this study, patients with ES-SCLC who received immunotherapy were assigned to receive either TRT or no TRT. TRT significantly improved progression-free survival (PFS), local recurrence-free survival (LRFS) and OS with well tolerated toxicity. Further sub-cohort analysis, TRT significantly improved LRFS in patients with oligo-metastasis and without liver metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics. CA Cancer J Clin. 72:7–33

    Article  PubMed  Google Scholar 

  2. Oronsky B, Reid TR, Oronsky A et al (2017) What’s New in SCLC? A review. Neoplasia. 19:842–847

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Byers LA, Rudin CM (2015) Small cell lung cancer: where do we go from here? Cancer. 121:664–672

    Article  CAS  PubMed  Google Scholar 

  4. Jeremic B, Shibamoto Y, Nikolic N et al (1999) Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol. 17:2092–2099

    Article  CAS  PubMed  Google Scholar 

  5. Slotman BJ, van Tinteren H, Praag JO et al (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 385:36–42

    Article  PubMed  Google Scholar 

  6. Slotman BJ, Faivre-Finn C, van Tinteren H et al (2017) Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: a secondary analysis of the phase III CREST trial. Lung Cancer. 108:150–153

    Article  PubMed  Google Scholar 

  7. Horn L, Mansfield AS, Szczesna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell Lung Cancer. N Engl J Med. 379:2220–2229

    Article  CAS  PubMed  Google Scholar 

  8. Goldman JW, Dvorkin M, Chen Y et al (2021) Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 22:51–65

    Article  CAS  PubMed  Google Scholar 

  9. Rudin CM, Awad MM, Navarro A et al (2020) Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line therapy for extensive-stage small-cell Lung Cancer: Randomized, Double-Blind, phase III KEYNOTE-604 study. J Clin Oncol. 38:2369–2379

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kasmann L, Eze C, Taugner J et al (2020) Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol. 15:167

    Article  PubMed  PubMed Central  Google Scholar 

  11. Spigel DR, Faivre-Finn C, Gray JE et al (2022) Five-year survival outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 40:1301–1311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhou Q, Chen M, Jiang O et al (2022) Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 23:209–219

    Article  CAS  PubMed  Google Scholar 

  13. Parsons LS Performing a 1:n case-control match on propensity score. Available at: https://support.sas.com/resources/papers/proceedings/proceedings/sugi29/165-29.pdf

  14. Ganti AKP, Loo BW, Bassetti M et al (2021) Small cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 19:1441–1464

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 394:1929–1939

    Article  CAS  PubMed  Google Scholar 

  16. Slotman B, Faivre-Finn C, Kramer G et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 357:664–672

    Article  CAS  PubMed  Google Scholar 

  17. Cheng Y, Han L, Wu L et al (2022) Effect of First-Line Serplulimab vs Placebo added to Chemotherapy on Survival in patients with extensive-stage small cell Lung Cancer: the ASTRUM-005 Randomized Clinical Trial. JAMA. 328:1223–1232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Liu SV, Reck M, Mansfield AS et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with atezolizumab, carboplatin, and Etoposide (IMpower133). J Clin Oncol. 39:619–630

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Xu LM, Cheng C, Kang M et al (2017) Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Sci Rep. 7:9255

    Article  PubMed  PubMed Central  Google Scholar 

  20. Zhang H, Deng L, Wang X et al (2019) Metastatic location of extensive stage small-cell lung cancer: implications for thoracic radiation. J Cancer Res Clin Oncol. 145:2605–2612

    Article  CAS  PubMed  Google Scholar 

  21. Welsh JW, Heymach JV, Chen D et al (2020) Phase I trial of Pembrolizumab and Radiation Therapy after induction chemotherapy for extensive-stage small cell Lung Cancer. J Thorac Oncol. 15:266–273

    Article  PubMed  Google Scholar 

  22. Diamond BH, Verma N, Shukla UC et al (2022) Consolidative thoracic Radiation Therapy after First-Line chemotherapy and immunotherapy in extensive-stage small cell Lung Cancer: a Multi-Ins titutional Case Series. Adv Radiat Oncol. 7:100883

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by National Natural Science Foundation (grant number 81703018) and Zhejiang Medical and Health Science and Technology Project (grant numbers 2022RC110 and 2023KY614).

Author information

Authors and Affiliations

  1. Department of Thoracic Radiotherapy, Key Laboratory of Radiation Oncology of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou, 310022, China

    Min Fang, Qing Gu, Huiwen Wu, Xianghui Du & Xiaojing Lai

  2. Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310018, China

    Min Fang, Le Wang, Qing Gu, Xianghui Du & Xiaojing Lai

  3. Department of Cancer Prevention, Zhejiang Cancer Hospital, Hangzhou, 310022, China

    Min Fang & Le Wang

Authors
  1. Min Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Le Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qing Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huiwen Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xianghui Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaojing Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Min Fang and Huiwen Wu wrote the main manuscript text and Le Wang prepared the Figs. 1, 2, 3 and 4. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Min Fang or Xiaojing Lai.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

10585_2023_10227_MOESM1_ESM.docx

Supplementary Material 1: Supplementary Table S1: Progression patterns of 95 patients.

10585_2023_10227_MOESM2_ESM.docx

Supplementary Material 2: Table S2. The clinical characteristics of 111 patients with ES-SCLC.

10585_2023_10227_MOESM3_ESM.docx

Supplementary Material 3: Table S3. The clinical characteristics of 99 patients with ES-SCLC before PSM.

10585_2023_10227_MOESM4_ESM.docx

Supplementary Material 4: Table S4. . The clinical characteristics of 66 patients with ES-SCLC after PSM.

Supplementary Material 5.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fang, M., Wang, L., Gu, Q. et al. Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world. Clin Exp Metastasis 40, 423–429 (2023). https://doi.org/10.1007/s10585-023-10227-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-023-10227-5

Keywords

Search

Navigation